ZAI LAB LTD

Chen Yajing’s recent 1,250‑share buy at ZAI LAB signals steady confidence in its oncology pipeline, reinforcing investor optimism for mid‑term upside.

Lis William’s recent sale of 8,506 Zai Lab ADS at $25.00 shows disciplined, rule‑based insider trading, reassuring investors of long‑term confidence in the biotech firm’s growth prospects.

Du Ying’s latest ZAI LAB trades signal routine vesting, not a strategic bet—insider activity remains neutral amid solid growth prospects.

Insider trading at Zai Lab shows CEO Du Ying’s liquidity‑managing buy‑sell‑buy cycle, with short‑term gains yet strong long‑term confidence in the biotech’s pipeline.

Insightful insider sales at Zai Lab reveal a tax‑covering move, not a distress signal, amid a 38% stock surge and biotech pipeline excitement.

Explore how Zai Lab insiders’ buying and selling of ADS shows strategic equity management and signals confidence in future oncology breakthroughs, balancing tax needs and long‑term commitment.

Du Ying’s rule‑based buying‑selling at Zai Lab reveals a mix of confidence and cash‑management, offering investors insight into the biotech’s short‑term tactics and long‑term outlook.

CEO Du Ying’s March 2026 trades show a mixed strategy—selling high‑priced ADS while buying low and buying back options—hinting insiders are capitalizing on short‑term gains while betting on future Zai Lab upside.